The committed equity facility provides a potential $40M lifeline but at the cost of severe dilution (~40% of shares outstanding registered). Watch for whether the company can close the $10M Catalyze payment by September 15, 2026 — failure would forfeit extension payments and trigger immediate payment demand. Monitor DOJ CID developments and any further cash burn acceleration.
Executive Summary
BioStem Technologies filed an S-1 registration statement to register up to 12,050,000 shares of common stock for resale by Roth Principal Investments, LLC, pursuant to a committed equity facility (Purchase Agreement) of up to $40 million over 36 months. The company is not selling shares itself in this offering and will not receive proceeds from Roth's resales, but may draw up to $40 million by selling shares to Roth at a 3-5% discount to VWAP. The filing reveals severe financial deterioration: H1 2026 revenue collapsed 48% YoY to $14.0M, the company posted a net loss of $17.8M (vs. $3.9M profit in H1 2025), and its auditor has issued a going-concern opinion due to a $39.0M accumulated deficit and a looming $10M Catalyze product payment. The stock faces massive potential dilution — the 12.05M registered shares represent ~40% of outstanding shares — and the company has received a DOJ Civil Investigative Demand under the False Claims Act.
Key Financial Metrics
Key Facts
- Registers up to 12,050,000 shares for resale by Roth Principal Investments under a $40M committed equity facility (Purchase Agreement dated September 18, 2026)
- Shares sold to Roth at 97% of VWAP (intraday) or 95% of VWAP (pre/post-market), subject to a $1.00 threshold price
- 12.05M registered shares represent ~40.2% of outstanding common stock as of September 17, 2026
- H1 2026 revenue declined 48% YoY to $14.0M; net loss of $17.8M vs. $3.9M profit in H1 2025
- Accumulated deficit of $39.0M as of June 30, 2026; auditor issued going-concern opinion
- CMS reimbursement change (flat $127.14/cm² effective Jan 1, 2026) reduced physician office revenue per cm² by up to 95%
- Company must pay up to $10M for Catalyze product rights by September 15, 2026 — payment not yet made
- Received DOJ Civil Investigative Demand under False Claims Act in September 2026
- May 2026 private placement includes price-based anti-dilution protection with a $0.70 floor
- Cash balance fell to $7.0M as of June 30, 2026 from $29.5M at year-end 2025
Financial Impact
H1 2026 revenue $14.0M (down 48% YoY), net loss $17.8M, accumulated deficit $39.0M, cash $7.0M, up to $40M potential equity facility with 3-5% VWAP discount, $10M Catalyze payment due
Risk Factors
- Going-concern risk with only $7.0M cash and $10M Catalyze payment due imminently
- Massive dilution risk — 12.05M registered shares represent ~40% of outstanding stock
- DOJ Civil Investigative Demand under False Claims Act could lead to material penalties
- CMS reimbursement change has permanently impaired physician office revenue (down 93% in H1 2026)
- May 2026 private placement anti-dilution provisions ($0.70 floor) complicate future financing
Investment Themes
Documents Analyzed
This report is based on 8 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| S-1 Filing (Primary) | 0001213900-26-101505 |
| Document: ea030505901ex-fee.htm | 0001213900-26-101505 |
| Document: ea030505901ex5-1.htm | 0001213900-26-101505 |
| Document: ea030505901ex23-1.htm | 0001213900-26-101505 |
| Document: ea030505901ex23-2.htm | 0001213900-26-101505 |
| Document: 0001213900-26-101505-index-headers.html | 0001213900-26-101505 |
| Document: 0001213900-26-101505-index.html | 0001213900-26-101505 |
| Document: 0001213900-26-101505.txt | 0001213900-26-101505 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 13, 2026 13d ago | EFFECT | $2.25 $2.11 | ▲ +6.22% | ▲ +5.14% | $1.55 (+31.11%) |
Oct 2, 2026 23d ago | S-1 | $2.76 $2.47 | ▲ +10.34% | ▲ +10.89% | $1.55 (+43.74%) |
Sep 30, 2026 25d ago | 8-K | $3.07 $2.73 | ▲ +11.07% | ▲ +11.81% | $1.55 (+49.51%) |
Sep 30, 2026 26d ago | EFFECT | $3.09 $3.07 | ▲ +0.65% | ▲ +0.83% | $1.55 (+49.84%) |
Sep 21, 2026 4w ago | Press Release | $3.98 $3.80 | ▼ −4.52% | ▼ −3.80% | $1.55 (−61.06%) |
Sep 18, 2026 5w ago | S-1 | $4.40 $3.98 | ▲ +9.55% | ▲ +9.53% | $1.55 (+64.77%) |
Sep 18, 2026 5w ago | Press Release | $4.74 $4.40 | ▲ +7.17% | ▲ +8.72% | $1.55 (+67.30%) |
Aug 14, 2026 10w ago | 3 | $3.00 $3.15 | ▲ +5.00% | ▲ +5.68% | $1.55 (−48.33%) |
Aug 14, 2026 10w ago | 3 | $3.00 $3.15 | ▲ +5.00% | ▲ +5.68% | $1.55 (−48.33%) |
Jul 29, 2026 12w ago | S-1 | $3.29 $3.20 | ▲ +2.74% | ▲ +4.41% | $1.55 (+52.89%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers